Integrated Wealth Concepts LLC Buys 4,241 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Integrated Wealth Concepts LLC lifted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 38.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,308 shares of the medical research company's stock after buying an additional 4,241 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Quest Diagnostics were worth $2,377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of DGX. Cetera Investment Advisers boosted its holdings in shares of Quest Diagnostics by 326.0% during the 1st quarter. Cetera Investment Advisers now owns 15,882 shares of the medical research company's stock valued at $2,114,000 after buying an additional 12,154 shares in the last quarter. Cetera Advisors LLC boosted its stake in Quest Diagnostics by 73.6% during the first quarter. Cetera Advisors LLC now owns 2,818 shares of the medical research company's stock worth $375,000 after acquiring an additional 1,195 shares in the last quarter. Mather Group LLC. grew its holdings in Quest Diagnostics by 63.7% in the second quarter. Mather Group LLC. now owns 709 shares of the medical research company's stock worth $94,000 after purchasing an additional 276 shares during the period. Simplicity Wealth LLC increased its stake in shares of Quest Diagnostics by 6.3% during the second quarter. Simplicity Wealth LLC now owns 1,938 shares of the medical research company's stock valued at $265,000 after purchasing an additional 115 shares in the last quarter. Finally, QRG Capital Management Inc. increased its stake in shares of Quest Diagnostics by 5.2% during the second quarter. QRG Capital Management Inc. now owns 43,606 shares of the medical research company's stock valued at $5,969,000 after purchasing an additional 2,148 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DGX has been the topic of several recent research reports. Citigroup upped their price target on Quest Diagnostics from $165.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. Evercore ISI initiated coverage on Quest Diagnostics in a report on Wednesday, August 28th. They set an "in-line" rating and a $165.00 price target for the company. Baird R W upgraded shares of Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 23rd. UBS Group increased their price target on shares of Quest Diagnostics from $165.00 to $166.00 and gave the company a "neutral" rating in a report on Wednesday, October 23rd. Finally, Mizuho boosted their price objective on shares of Quest Diagnostics from $160.00 to $174.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Nine research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $164.58.

Insider Activity

In other Quest Diagnostics news, CAO Michael J. Deppe sold 18,755 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total value of $2,889,207.75. Following the completion of the sale, the chief accounting officer now owns 34,941 shares in the company, valued at approximately $5,382,661.05. This represents a 34.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Karthik Kuppusamy sold 1,775 shares of the business's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $156.92, for a total value of $278,533.00. Following the completion of the transaction, the senior vice president now owns 9,734 shares in the company, valued at $1,527,459.28. The trade was a 15.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.79% of the company's stock.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock traded down $1.17 during trading hours on Friday, reaching $157.35. 951,373 shares of the stock traded hands, compared to its average volume of 835,314. The company has a 50 day moving average price of $156.24 and a 200 day moving average price of $149.76. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $17.56 billion, a price-to-earnings ratio of 21.15, a P/E/G ratio of 2.77 and a beta of 0.89. Quest Diagnostics Incorporated has a one year low of $123.04 and a one year high of $165.32.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.25%. The firm had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities research analysts expect that Quest Diagnostics Incorporated will post 8.9 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 29th. Stockholders of record on Tuesday, January 14th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.91%. The ex-dividend date of this dividend is Tuesday, January 14th. Quest Diagnostics's dividend payout ratio (DPR) is currently 40.32%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.